Treatment of female schizophrenic patients with bromperidol, a new neuroleptic drug of the butyrophenone group with medium duration of action.
Bromperidol has a safe antipsychotic effect. The latency is short, the effect is definite on the seventh treatment day and is already seen in particular symptoms on the third treatment day. Beside the antipsychotic effect, the substance has slight sedative properties, an anxiolytic effect and an evident influence on the complex phenomenon of social re-integration. The sedative effect is not sufficient in severe psychomotor agitation; here it is necessary to combine it with a sedative neuroleptic or other sedating substance. The clinical effect is safe for 24 hours. Due to the small doses (3-12 mg daily), bromperidol belongs to the neuroleptics of high potency. The high potency, the 24 hour efficiency and the low sedation qualify the substance for the long-term treatment of schizophrenic psychoses. Extrapyramidal effects occur in relation to the high potency and are easily corrected by an anticholinergic drug.
D000328:Adult; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*
D006220:Haloperidol